Additional disclosures on 11.7 lakh convertible warrants preferential issue
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Senores Pharmaceuticals has filed additional disclosures to its EGM notice dated January 7, 2026 regarding the issue and allotment of 11,70,000 convertible equity warrants via preferential issue on private placement basis. The company clarified the floor price methodology, noting its Articles of Association required a valuation report from a registered valuer. Maitri Valuation determined the fair market value at Rs 812 per share, using 100 percent weightage to the market approach as other valuation methods yielded lower values. The issue represents less than 5 percent of post-issue diluted capital.
Clarification on warrant pricing methodology; floor price set at Rs 812 per share based on market approach valuation.